News Search Results

Displaying Results 1376-1400 of 4489 "biotechnology"

Oct 31, 2025, 06:30 ET Agriculture Biotechnology Market worth $144.25 billion by 2030- Exclusive Report by MarketsandMarkets™

Plant and microbial biotechnology to hold significant share during forecast period. The plant biotechnology and microbial biotechnology segments are expected to hold a significant share of the agriculture biotechnology market during the forecast

More news about: MarketsandMarkets


Oct 30, 2025, 21:08 ET Stockholder Alert: Robbins LLP Informs Investors of the Avantor, Inc. Class Action Lawsuit

AVTR) common stock between March 5, 2024 and October 28, 2025. Avantor provides scientific products and services for customers in biotechnology, pharmaceuticals, healthcare, education, government, and other industries.

More news about: Robbins LLP


Oct 30, 2025, 18:00 ET Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.

More news about: Nektar Therapeutics


Oct 30, 2025, 17:30 ET Revenue Cycle Management (RCM) Market to Grow at 45.95% CAGR, Surpassing USD 28560 Billion by 2035 | Vantage Market Research

market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize

More news about: Vantage Market Research


Oct 30, 2025, 16:54 ET BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M

receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about

More news about: BioVaxys Technology Corp.


Oct 30, 2025, 16:15 ET NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

Oren, and Tammy Galili. About NewcelXNewcelX Ltd. (NASDAQ: NCEL) is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated

More news about: NewCelX Ltd.; NLS Pharmaceutics Ltd.; Kadimastem Ltd.


Oct 30, 2025, 16:00 ET Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025

LEXINGTON, Mass., Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company

More news about: Curis, Inc.


Oct 30, 2025, 10:00 ET Pillar Biosciences Announce Automated NGS Library Preparation Method on Hamilton Microlab STAR to Accelerate Myeloproliferative Neoplasm Research

solutions, small devices, consumables, and OEM liquid handling solutions. Known for advancing life science, clinical diagnostics, forensics and biotechnology industries, Hamilton products offer reliability, performance, and flexibility. Ensuring a continuous commitment to quality, Hamilton utilizes state-of-the-art

More news about: Pillar Biosciences, Inc.


Oct 30, 2025, 09:00 ET Signant Health Appoints Internationally Recognized Cognitive Assessment Expert John Harrison to Further Advance Innovation in CNS Clinical Trials

endpoints play a central role in regulatory decision-making. John brings extensive experience partnering with pharmaceutical and biotechnology companies to design and implement cognitive testing strategies in clinical trials. He holds dual academic appointments at Amsterdam UMC in the Netherlands

More news about: Signant Health


Oct 30, 2025, 09:00 ET Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

About Kiora Pharmaceuticals Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules

More news about: RARE-X


Oct 30, 2025, 08:48 ET MLTX INVESTOR ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman

The litigation is focused on the propriety of MoonLake's statements about the trial design and data for SLK. The clinical stage biotechnology company is focused on skin inflammatory diseases driven by a cytokines known as IL-17A and IL-17F. Central to SLK's commercial

More news about: Hagens Berman Sobol Shapiro LLP


Oct 30, 2025, 08:33 ET STEMup Science and Technology Institute™ and Connexis Search Group Launch National Partnership to Advance Fractional Leadership and Workforce Innovation in STEM and Life Sciences

seeking flexible career and advisory roles within high-growth ventures. The initiative will pilot fractional executive placements within biotechnology and technology companies while expanding STEMup's Pittsburgh Innovators Apprenticeship Program™ (PIAP™)—a workforce pipeline integrating

More news about: STEMup Science & Technology Institute


Oct 30, 2025, 08:30 ET NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression

NeuroKaire, a pioneer in precision psychiatry and neurology, has launched an R&D collaboration with Compass Pathways, a leading biotechnology company dedicated to transforming mental health care.  

More news about: NeuroKaire


Oct 30, 2025, 08:30 ET Using Acceleration Levers to Expedite Late Phase CMC Programs for Therapeutic Proteins, Upcoming Webinar Hosted by Xtalks

the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access

More news about: Xtalks


Oct 30, 2025, 08:30 ET Real-World Clinical Data and Cohort Design, Upcoming Webinar Hosted by Xtalks

the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access

More news about: Xtalks


Oct 30, 2025, 08:30 ET Biomarker-Driven Therapy Launch Strategies for Global Success, Upcoming Webinar Hosted by Xtalks

the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access

More news about: Xtalks


Oct 30, 2025, 08:00 ET Brenig Therapeutics Names Megan McGill as Chief Executive Officer

Therapeutics Founded in 2021 and based in Somerville, MA, Brenig Therapeutics is a biotechnology company committed to pioneering innovative small-molecule therapies for neurodegenerative diseases. Through advanced science and leading AI and

More news about: Brenig Therapeutics Inc


Oct 30, 2025, 07:30 ET Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

Oct. 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates

More news about: Intensity Therapeutics Inc.


Oct 30, 2025, 07:24 ET GITEX Marks Major Expansion with Four New Global Editions Bridging Fast-Rising AI and Tech Ecosystems Worldwide

unicorns in India. Hosted by and organised in partnership with the Government of Karnataka's Department of Electronics, Information Technology and Biotechnology, K-TECH, and Startup Karnataka, the event will serve as a catalyst for global collaboration across AI, semiconductors, advanced manufacturing, quantum

More news about: GITEX


Oct 30, 2025, 07:10 ET GITEX Marks Major Expansion with Four New Global Editions Bridging Fast-Rising AI and Tech Ecosystems Worldwide

unicorns in India. Hosted by and organised in partnership with the Government of Karnataka's Department of Electronics, Information Technology and Biotechnology, K-TECH, and Startup Karnataka, the event will serve as a catalyst for global collaboration across AI, semiconductors, advanced manufacturing, quantum

More news about: GITEX


Oct 30, 2025, 07:05 ET REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

NAVXpress® suspension-based platform process. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered

More news about: REGENXBIO Inc.


Oct 30, 2025, 07:00 ET NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders, and Aexon Labs, a biotechnology company advancing next-generation central nervous system ("CNS") therapeutics, today announced the expansion of their DOXA platform with the AEX-6xx

More news about: NLS Pharmaceutics Ltd.


Oct 30, 2025, 07:00 ET Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update

Science's 2025 Top Employers Survey, marking the fifth consecutive year in which Insmed achieved the top ranking. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics.

More news about: Insmed Incorporated


Oct 30, 2025, 06:45 ET Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance

Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem (

More news about: Eli Lilly and Company


Oct 30, 2025, 06:30 ET Evommune Announces Commencement of Initial Public Offering

PALO ALTO, Calif., Oct. 30, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that on October 17, 2025, it filed

More news about: Evommune, Inc


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.